| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10012855 | HBV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS30086527 | HIV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS30030617 | HIV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS30020028 | HIV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS30030618 | HIV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS20004010 | HPV | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS44002102 | HTLV-1 | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS44017389 | HTLV-1 | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS44001758 | HTLV-1 | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
| TVIS44002820 | HTLV-1 | ENSG00000172890.13 | protein_coding | NADSYN1 | No | No | 55191 | Q6IA69 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | NADSYN1 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0002244 |
| UniProt ID | Q6IA69 |
| Regulation Type | product of |
| PubMed IDs | 19647806 |
| Citations | Resto M, Yaffe J, Gerratana B: An ancestral glutamine-dependent NAD(+) synthetase revealed by poor kinetic synergism. Biochim Biophys Acta. 2009 Nov;1794(11):1648-53. doi: 10.1016/j.bbapap.2009.07.014. Epub 2009 Aug 6. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
